Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Indonesia
85%
Rifampicin
83%
Plasma Concentration
77%
Clinical Trials
75%
Atrial Natriuretic Peptide
75%
Sprague-Dawley Rats
63%
Jakarta
60%
Cardioprotection
55%
Healthy Volunteers
50%
Extracellular Volume
50%
Mangiferin
50%
Internal Medicine Wards
50%
Pre-diabetes (pre-DM)
50%
Primaquine
50%
Ritonavir
50%
L-NAME
50%
Double-blind Randomized Controlled Trial
50%
Doxorubicin
50%
Angiotensin II (Ang II)
50%
Andrographis Paniculata
50%
Oxidative Stress
50%
Losartan
45%
Adverse Drug Reaction
43%
Pioglitazone
43%
Efavirenz
43%
Placebo
42%
Asian Population
39%
Hematocrit
38%
Safety Profile
37%
Drug Administration
37%
Nevirapine
37%
Enalapril
35%
Renin-angiotensin System
34%
Hypertension
34%
Co-infected Patients
33%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
31%
Asian Patients
31%
Angiotensin
30%
Ejection Fraction
30%
Antioxidant Effect
30%
Prospective Cohort Study
30%
Nicardipine
29%
Elderly Patients
29%
Dipeptidyl peptidase-4 (DPP-4)
28%
Retrospective Cohort Study
28%
MRNA Expression
28%
Single-dose Studies
27%
Adrenoceptors
27%
Postprandial Glucose
25%
Pharmacology, Toxicology and Pharmaceutical Science
Rifampicin
83%
Clinical Trial
79%
Non Insulin Dependent Diabetes Mellitus
75%
Adverse Event
72%
Sprague Dawley Rat
63%
Randomized Controlled Trial
59%
Observational Study
59%
Adverse Drug Reaction
56%
Primaquine
50%
Ritonavir
50%
Doxorubicin
50%
Mangiferin
50%
Angiotensin
50%
Normal Human
50%
Atrial Natriuretic Factor
50%
Andrographis paniculata
50%
Placebo
48%
Cardiomyopathy
45%
Pioglitazone
43%
HIV
43%
Efavirenz
43%
Antioxidant
42%
Drug Administration
41%
Cardiovascular Disease
40%
Nevirapine
37%
Arginine Methyl Ester
37%
Angiotensin II
37%
Renin
37%
Drug Interaction
36%
Inflammation
35%
Diabetes Mellitus
35%
Heart Failure
34%
Nicardipine
33%
Losartan
33%
Incretin
30%
Combination Therapy
30%
Nitric Oxide
29%
Adrenergic Receptor
29%
Retrospective Study
29%
Creatinine
29%
Glucagon-Like Peptide-1
28%
Pharmacokinetics
28%
Cohort Study
28%
Breast Cancer
25%
Synthetase
25%
Myostatin
25%
Amiodarone
25%
Advanced Glycation End Product
25%
Endoxifen
25%
QT Prolongation
25%